Moreover, given the generally decreased 5-HT and 5-HIAA levels, as well as 5-HIAA/5-HT turnover ratios, measured in our study, combined with the formerly suggested counteracting mechanisms of upregulated postsynaptic 5-HT1A receptors and relatively preserved 5-HTT reuptake sites, a concurrent pharmacological treatment using an SSRI and a 5-HT1A receptor antagonist might indeed effectively alleviate depressive symptoms in DLB patients [25]. Here, SLC6A4 is linked to Lewy body dementia.